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Abstract: A pexiganan–chitosan conjugate was designed to combine the
exceptional bioadhesion and tissue-regenerating abilities of chitosan with the
excellent antibiotic properties of pexiganan. We herein report our first results
on the successful synthesis, including Fourier transform infrared (FT-IR) and
amino acid analysis of such conjugate, which was prepared by regioselective
covalent attachment of a Cys-containing pexiganan analog to the chitosan’s
amino groups. Further results from ongoing research will be reported.
Keywords: Antimicrobials, biopolymers, chitosan, diabetes, drug delivery,
peptides, pexiganan
INTRODUCTION
Pexiganan (or MSI-78) is a 22-amino acid linear analog of magainin-2, a
natural antimicrobial peptide isolated from the skin of the African clawed
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frog, Xenopus laevis.[1–3] Pexiganan is remarkably effective against
more than 3,000 species of gram-positive and gram-negative bacteria
that cause infections on skin and soft tissues, including methicillin-
resistant Staphylococcus aureus (MRSA), and has no propensity to
induce bacterial resistance. In two phase III clinical trials involving 835
patients with infected diabetic foot ulcers, both topical pexiganan ace-
tate 1% and oral ofloxacin (800mg=day) achieved clinical cure or
improvement in 90% of patients, so it rapidly underwent commercial
development for topical application as a cream (pexiganan acetate
1%).[4] However, in 1990, the U.S. Food and Drug Administration denied
its approval on the basis that its effectiveness in completely eradica-
ting the pathogen (66% of treated patients) was not higher than that
achieved by ofloxacin taken orally (82% of treated patients),[5] which
led the industrial developer (Genaera Corporation, formerly Magainin
Pharmaceutical Inc.) to abandon the production of pexiganan acetate.
Even so, the very large and growing incidence of diabetes in north-
western countries, together with the lack of valuable topical antimicro-
bials to treat infected diabetic foot ulcers and the well-known
problems associated with oral drug delivery, makes further exploration
of pexiganan-based systems worthwhile, explaining the recent (October
2007) acquisition by the U.S. pharmaceutical corporation MacroChem
of the exclusive option to license pexiganan worldwide.[6] This was
followed by the latest (as of 13 March 2008) press release on new phase
III clinical trials promoted by this company that confirm the efficacy of
pexiganan to be statistically equivalent to that of oral antibiotic
therapy.[7]
Taking advantage of our prior experience in the synthesis and study
of antimicrobial peptides,[8–10] as well as in the development of novel
chitosan-based biopolymers for biomedical applications,[11–13] we decided
to break through to the preparation of a novel chitosan–pexiganan con-
jugate with potential application in the topical treatment of infected dia-
betic foot ulcers. We hope such a conjugate will combine the excellent
antimicrobial properties of pexiganan with the well-known biocompat-
ibility and skin-injury-healing ability of chitosan. Chitosan-based materi-
als have been used for several biomedical purposes, including drug
delivery, vascular grafts, cartilage regeneration, sutures, and wound-
healing materials, because among chitosan’s most appealing char-
acteristics are its bioadhesive and self-aggregation properties, as well as
its ability to enhance cell proliferation, thus promoting tissue regenera-
tion.[14–25] In 2004, Gopinath et al. reported pexiganan-incorporated
collagen matrices that led to improvement of tissue reconstruction in
infected wounds in mice as compared to collagen films alone.[26] How-
ever, so far nothing has been attempted concerning the development of
Chitosan–Pexiganan Conjugate 1229
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pexiganan–biopolymer conjugates where this peptide is covalently
attached to the polymer matrix. This communication reports our primary
results concerning the synthesis and characterization by Fourier
transform infrared (FT-IR) spectroscopy and amino acid analysis
(AAA) of a covalent pexiganan–chitosan conjugate. Further results from
ongoing physicochemical, morphological, and biological studies on this
conjugate will be eventually published as a full paper.
MATERIALS AND METHODS
Chemicals
4-Methylbenzhydrylamine (MBHA) LL resin (100–200 mesh), p-{(R,S)-
a-[1-(9H-fluoren-9-yl)-methoxyformamido]-2,4-dimethoxybenzyl}-phe-
noxyacetic acid (Fmoc-Rink) linker, Fmoc-protected amino acids
(Fmoc-AA-OH), and N,N,N0,N0-tetramethyluronium tetrafluoroborate
(TBTU) were all from NovaBiochem (VWR International, Lisbon,
Portugal). (N-e-Maleimidocaproyloxy)-sulfosuccinimide ester (Sulfo-
EMCS) was from Pierce (Sopachem, Ap Ochten, the Netherlands).
Low-molecular-weight chitosan from coarse ground crab (150 kDa,
degree of acetylation 0.10, 4.86 mmol –NH2 groups=g; ref. 44.886-9),
N-ethyl-N,N-diisopropylamine (DIEA), EDTA, piperidine, triisopropyl-
silane (TIS), trifluoroacetic acid (TFA), KBr (p.a., for IR spectroscopy
grade), and all remaining common chemicals and solvents (p.a. quality)
were from Sigma-Aldrich (Lisbon, Portugal). The dialysis mem-
brane (MW cutoff 12–14 kDa) was from Medicel International
(London, UK).
Instrumentation
FT-IR spectra were recorded from KBr pellets of pexiganan and
pexiganan–chitosan on a Jasco FT=IR-460 instrument (each spectrum,
run in duplicate, was obtained from 32 scans between 4000 and
400 cm1 at a resolution of 4 cm1). AAA of peptide and peptide–chito-
san hydrolysates was carried out on a Beckman 6300 amino acid analy-
zer. Mass spectra (MS) were obtained by the matrix-assisted laser
desorption ionization–time-of-flight (MALDI-TOF) technique on a
MALDI-TOF Voyager DE Perspective spectrometer from Applied Bio-
systems. High-performance liquid chromatographic (HPLC) analyses
were run on an analytical Beckman System Gold, and peptide puri-
fication was carried out on a preparative HPLC Waters DeltaPrep
1230 M. K. S. Batista et al.
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4000 system, using C-18 reverse-phase columns. Peptide and peptide–
chitosan conjugate were freeze-dried on a Christ alpha l-4 lyophilizer.
Peptide Synthesis
Pexiganan-Ala-Ala-Cys amide (Gly-Ile-Gly-Lys-Phe-Leu-Lys-Ala-Lys-
Lys-Phe-Gly-Lys-Ala-Phe-Val-Lys-Ile-Leu-Lys-Lys-Ala-Ala-Cys-NH2;
molecular weight, 2721 Da) was synthesized manually on a Fmoc-Rink-
MBHA resin by standard Fmoc=tBu solid-phase peptide synthesis
(SPPS) strategies.[8,9] The target peptide was isolated from the crude
mixture by preparative HPLC and characterized by analytical HPLC,
AAA, and MALDI-TOF MS (data not shown).
Modification of Chitosan with the Sulfo-EMCS Cross-Linker
Chitosan (10 mmol –NH2 groups) was dissolved in acetic acid=sodium
acetate buffer at pH 6.0 (1 ml), and phosphate-buffered saline (PBS) buffer
(pH 7.4, 5 ml) was added to the solution together with EDTA (5 mmol).
The mixture was put under vigorous stirring at 4 C, and Sulfo-EMCS
(70 mmol) was then slowly added to the solution. The reaction was
allowed to proceed at 4 C for 30min and then at room temperature for
90min. The solution was then dialyzed against PBS over 24 hours (three
buffer renewals) and then immediately used in the subsequent reaction.
Attachment of Pexiganan-Ala-Ala-Cys to the Modified Chitosan
The modified chitosan solution, obtained as described in the previous sec-
tion, was put under vigorous stirring at 4 C. The peptide (3.2 mmol) was
then slowly added to the solution, and the reaction was allowed to evolve
at 4 C for 30min and then at room temperature for a further 90min. The
reaction was quenched by addition of free cysteine 100mM in PBS (1 ml)
and further reaction for 15min at room temperature. The final mixture
was dialyzed against PBS (2 days, four buffer renewals) and then against
deionized water (3 days, six solvent renewals), after which it was freeze-
dried and characterized by FT-IR.
Analysis of the Peptide and the Peptide–Chitosan Conjugate by AAA
The amount of peptide and its amino acid composition, for both the pure
peptide and its chitosan conjugate, were determined by standard AAA
Chitosan–Pexiganan Conjugate 1231
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procedures.[8,9] Briefly, a known amount of the sample was submitted to
acid hydrolysis in aqueous HCl 6M containing 1mM of aminobutyric
acid as internal reference. The hydrolysis was carried out in a sealed glass
tube at 100 C and over 24 h, for full cleavage of peptide bonds and con-
comitant quantitative release of the amino acids. The hydrolysate was
then evaporated to dryness, and the residue was retaken with a known
volume of citric acid=sodium citrate buffer (60mM, pH 2), of which,
after adequate dilutions, a known aliquot was filtered through a nylon
filter (Ø¼ 0.45 mm) and injected into the analyzer.
RESULTS AND DISCUSSION
The preparation of covalent peptide and protein conjugates is often
accomplished by means of maleimide-based crosslinkers.[27,28] Other ele-
gant approaches include enzyme-catalyzed conjugations, such as the pre-
paration of a gelatin–chitosan conjugate through tyrosinase-mediated
conversion of Tyr residues into their reactive o-quinone moieties.[29]
Recently, Masuko et al. used N-e-maleimidocaproyloxy-sulfosuccinimide
ester (Sulfo-EMCS) to promote the attachment of bovine serum albumin
(BSA) to thiolated chitosan.[30] Thus, we have investigated whether it was
possible to prepare a pexiganan–chitosan conjugate by a similar proce-
dure, but in our case using unmodified chitosan and a pexiganan analog
having an additional C-terminal Ala-Ala-Cys segment to provide the
peptide the Cys thiol necessary to accomplish the desired reaction
(Scheme 1). The target peptide was successfully synthesized and isolated
(not shown), and its attachment to unmodified chitosan was then pro-
moted by Sulfo-EMCS, yielding a product that was characterized by
FT-IR and AAA.
The FT-IR spectrum of chitosan (Fig. 1a) is characterized by a large
and intense band at 3450–3200 cm1(hydrogen-bonded O-H stretching
and N–H stretching bands, with maximal absorption at 3376 cm1) par-
tially overlapped with C–H stretching bands at 2800 cm1; bands due to
the N-acetyl-D-glucosamine (GlcNHAc) units, with amide I (C¼O
stretching) at 1645 cm1, amide II (N–H bending) at 1557 cm1, amide III
(CN stretching coupled with N–H plane deformation) at 1412 cm1 and
symmetrical angular deformation of –CH3 at 1384 cm
1; C–N stretching
of the amino groups at 1325 cm1; O–H plane deformation at 1259 cm1;
C–O stretching band at 1078 cm1; C–O–C stretching vibration in the
glucopyranose ring at 1030 cm1; and the specific bands of the b(1! 4)
glycoside bridge at 1153 cm1 and 899 cm1.[12,13] In comparison, the
FT-IR spectrum of the peptide conjugate (Fig. 1b), while still displaying
the characteristic bands due to the polysacharide chains (O–H bending at
1232 M. K. S. Batista et al.
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1252 cm1, C–O stretching at 1079 cm1, C–O–C stretching vibration in
the glucopyranose ring at 1036 cm1 and the specific bands of the
b(1! 4) glycoside bridge at 1153 cm1 and 899 cm1), it also exhibits sig-
nificant differences as compared to the spectrum of the parent polymer.
For instance, the large and intense O–HþN–H stretching band has its
maximal absorption shifted down to 3289 cm1 (D¼87 cm1), which
certainly reflects the significant contribution from N–H stretching vibra-
tions due to the primary amino groups from the N-terminal amino acid
and Lys side-chains (10 groups per peptide chain) and to the amide bonds
(25 secondary plus 1 primary amide groups per peptide chain); this inter-
pretation is reinforced by the changes registered in the amide I and amide II
bands, whose relative intensities are dramatically changed from one spec-
trum to the other, as these are the two most intense bands in the spectrum
of the peptide–chitosan conjugate, but not in the spectrum of unmodified
chitosan. The wavenumbers for the amide I and amide II bands are also
different in the conjugate, where they appear at 1653 (D¼þ8 cm1) and
1541 cm1 (D¼16 cm1), respectively. If we go further and take a look
at the hyperfine structure of the conjugate’s amide I band (inset in
Scheme 1. Modification of chitosan D-glucosamine units by sulfo-EMCS
and subsequent attachment of pexiganan-Ala-Ala-Cys through its C-terminal
Cys thiol.
Chitosan–Pexiganan Conjugate 1233
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Fig. 1b), we find that it reflects the contributions of the different amide
bonds present and of peptide secondary structure determinants. In fact,
the bands at 1682, 1659, and 1636 cm1 observed in the present case
are close to those reported by Shanmugam et al. for the FT-IR absorp-
tion spectrum of pexiganan in methanol, respectively, at 1680, 1659,
and 1630 cm1,[31] with slight differences probably due to the additional
C-terminal Ala-Ala-Cys stretch in our peptide. These authors have ana-
lyzed the structure of pexiganan in aqueous and different organic media
using FT-IR absorption and other spectroscopic techniques and found
Figure 1. FT-IR spectra acquired from KBr pellets of (a) chitosan and (b)
pexiganan–chitosan conjugate.
1234 M. K. S. Batista et al.
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that this peptide exhibits conformational polymorphic behavior in differ-
ent solvents, which is reflected on the wavenumbers associated to peaks
in the amide I region. Thus, a comparison of our data with those from
these authors would suggest the peptide adopt a dominant b-sheet struc-
ture with b-turn and minor a-helix content, when inserted into the chito-
san matrix.[31] However, this hypothesis must be regarded with some
caution, as our spectra were acquired from KBr pellets, a procedure that
has been previously found to change protein structure from a-helix to
b-sheet.[32] Additional information on peptide secondary structure within
the chitosan matrix can be withdrawn from the amide III region. In fact,
among the spectral regions arising out of vibrational modes of amide
bonds, amide I and amide III bands are the most sensitive to variations
in secondary structure folding. The amide I region from spectra of pro-
teins and peptides suffers from several limitations, including interference
with bands from water or hydroxylated solvents, and a relatively unstruc-
tured contour due to overlap of orbital bands that arise from various sec-
ondary structures; yet, it is still the most commonly used for secondary
structure analysis, given its high intensity. In contrast, the corresponding
amide III region (1350–1200 cm1), although fairly weak in intensity, is
not affected by these constraints, so it should be preferred to gain reliable
information on peptide secondary structure.[32,33] This region is quite
different between both spectra displayed in Figs. 1a and b, attesting the
significant alterations brought by peptide insertion. Thus, amide III
bands arise at 1356–1306 cm1 in the peptide conjugate, which, according
to Cai and Singh, reflects a predominant peptide a-helical structure.[33]
This interpretation follows the opposite direction of that given by
the analysis of the amide I region, reinforcing the need to analyze these
data with caution, at least concerning peptide secondary structure
predictions.
Finally, differences in the C–H stretching region are also noteworthy:
in contrast to what is observed in the spectrum of chitosan, the FT-IR
spectrum for the peptide conjugate exhibits three perfectly defined bands
at 3060, 2950, and 2892 cm1, attributed to C–H stretching vibrations in,
respectively, aromatic, methylene, and methyl groups, most probably
from the side chains of the aromatic amino acid Phe (three per peptide
chain) and of aliphatic amino acids such as Leu, Ile, Val, Ala and Lys.
C–C (aliphatic and aromatic) stretching vibrations are hindered by amide
I and II bands, but a C–C in-ring stretching, typical of aromatics, can still
be distinguished at 1458 cm1.
In view of this, FT-IR data alone definitely support the successful
insertion of the peptide into the chitosan matrix. Still, characterization
of the peptide-chitosan conjugate by AAA provided the ultimate proof
of a profitable attachment of the antimicrobial peptide to the polymer.
Chitosan–Pexiganan Conjugate 1235
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Thus, as shown in Table 1, acid hydrolysis of the product allowed
determining the amino acids whose identities and relative proportions
fully agree with what was expected from the peptide sequence.
Overall, we established an easy, fast, and profitable method for the
covalent attachment of pexiganan to chitosan. An alternative approach
would be the synthesis of the peptide as a C-terminal carboxyl and then
its attachment to the chitosan’s amino groups by means of condensation
agents such as a water-soluble carbodiimide,[34] which has been used in
polymer chemistry as a cross-linking agent[35–37] and also to attach other
peptides to the chitosan matrix.[38] However, both the peptide N-terminal
a-amine and Lys-side chain e-amino groups would be reactive under
those conditions, and extensive cross-linking between peptide chains
would most probably occur. To overcome this problem, a fully protected
peptide analog, assembled on an acid hyperlabile resin such as 2-chloro-
trityl chloride (2-CTC) resin,[39] could be used; but then peptide’s solubi-
lity in aqueous media would be minimal, so the condensation to chitosan
should be carried out in a suitable organic solvent such as DCM. This, in
turn, would require the conversion of chitosan (insoluble in current
organic media) into a suitable organic-soluble derivative, such as O-
trityl-chitosan.[40–43] Taken together, these considerations show that our
route for peptide insertion into the polymer matrix is incontestably
advantageous, as it is regioselective, where only the sulfo-EMCS-
activated amino groups of chitosan will be able to react exclusively with
the peptide Cys-side chain thiol groups. This offers an efficient and con-
trolled attachment of the peptide with minimal, if any, perturbation of its
bioactive sequence.
Table 1. Amino acid composition of the peptide–chitosan conjugate
Relative proportion
Amino acidresiduea Concentrationb (mM) Experimental Expectedc
Gly 0.4240 3.25 3
Ala 0.5230 4.00 4
Val 0.1271 0.97 1
Ile 0.2461 1.88 2
Leu 0.2596 1.99 2
Phe 0.3899 2.98 3
Lys 1.661 8.93 9
aCys was not considered, as its quantitation by AAA is not reliable.
bIn injected sample, after known dilutions of the original hydrolysate.
cFrom the pexiganan-Ala-Ala-Cys amino acid sequence.
1236 M. K. S. Batista et al.
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CONCLUSION
We have successfully achieved the synthesis (FT-IR and AAA) of a
pexiganan–chitosan conjugate prepared by regioselective attachment of
a Cys-containing pexiganan analog to the chitosan’s amino groups.
The conjugate will most probably find clinical application for topical
treatment of infected diabetic foot ulcers and other skin injuries, as it
combines the well-known antimicrobial potency of pexiganan with the
remarkable properties of chitosan for bioadhesion and tissue regenera-
tion. Results from ongoing biological studies toward this goal will be
reported in due course.
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